Genetic basis of potential therapeutic strategies for craniosynostosis

Heather Melville, Yingli Wang, Peter J. Taub, Ethylin Wang Jabs

Research output: Contribution to journalArticle

Abstract

Craniosynostosis, the premature fusion of one or more cranial sutures, is a common malformation of the skull that can result in facial deformity and increased intracranial pressure. Syndromic craniosynostosis is present in -15% of craniosynostosis patients and often is clinically diagnosed by neurocranial phenotype as well as various other skeletal abnormalities. The most common genetic mutations identified in syndromic craniosynostosis involve the fibroblast growth factor receptor (FGFR) family with other mutations occurring in genes for transcription factors TWIST, MSX2, and GLI3, and other proteins EFNB1, RAB23, RECQL4, and POR, presumed to be involved either upstream or downstream of the FGFR signaling pathway. Both syndromic and nonsyndromic craniosynostosis patients require early diagnosis and intervention. The premature suture fusion can impose pressure on the growing brain and cause continued abnormal postnatal craniofacial development. Currently, treatment options for craniosynostosis are almost exclusively surgical. Serious complications can occur in infants requiring either open or endoscopic repair and therefore the development of nonsurgical techniques is highly desirable although arguably difficult to design and implement. Genetic studies of aberrant signaling caused by mutations underlying craniosynostosis in in vitro calvarial culture and in vivo animal model systems have provided promising targets in designing genetic and pharmacologic strategies for systemic or adjuvant nonsurgical treatment. Here we will review the current literature and provide insights to future possibilities and limitations of therapeutic applications.

Original languageEnglish (US)
Pages (from-to)3007-3015
Number of pages9
JournalAmerican Journal of Medical Genetics, Part A
Volume152 A
Issue number12
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Craniosynostoses
Fibroblast Growth Factor Receptors
Mutation
Therapeutics
Cranial Sutures
Intracranial Pressure
Skull
Sutures
Early Diagnosis
Transcription Factors
Animal Models
Phenotype
Pressure
Brain
Genes

Keywords

  • Apert syndrome
  • Craniosynostosis
  • Fibroblast growth factor receptor
  • Inhibitor
  • Mutation
  • Surgery
  • Treatment

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Genetic basis of potential therapeutic strategies for craniosynostosis. / Melville, Heather; Wang, Yingli; Taub, Peter J.; Jabs, Ethylin Wang.

In: American Journal of Medical Genetics, Part A, Vol. 152 A, No. 12, 12.2010, p. 3007-3015.

Research output: Contribution to journalArticle

Melville, Heather ; Wang, Yingli ; Taub, Peter J. ; Jabs, Ethylin Wang. / Genetic basis of potential therapeutic strategies for craniosynostosis. In: American Journal of Medical Genetics, Part A. 2010 ; Vol. 152 A, No. 12. pp. 3007-3015.
@article{701f7d8cf38f4f51a063b60a7f27d027,
title = "Genetic basis of potential therapeutic strategies for craniosynostosis",
abstract = "Craniosynostosis, the premature fusion of one or more cranial sutures, is a common malformation of the skull that can result in facial deformity and increased intracranial pressure. Syndromic craniosynostosis is present in -15{\%} of craniosynostosis patients and often is clinically diagnosed by neurocranial phenotype as well as various other skeletal abnormalities. The most common genetic mutations identified in syndromic craniosynostosis involve the fibroblast growth factor receptor (FGFR) family with other mutations occurring in genes for transcription factors TWIST, MSX2, and GLI3, and other proteins EFNB1, RAB23, RECQL4, and POR, presumed to be involved either upstream or downstream of the FGFR signaling pathway. Both syndromic and nonsyndromic craniosynostosis patients require early diagnosis and intervention. The premature suture fusion can impose pressure on the growing brain and cause continued abnormal postnatal craniofacial development. Currently, treatment options for craniosynostosis are almost exclusively surgical. Serious complications can occur in infants requiring either open or endoscopic repair and therefore the development of nonsurgical techniques is highly desirable although arguably difficult to design and implement. Genetic studies of aberrant signaling caused by mutations underlying craniosynostosis in in vitro calvarial culture and in vivo animal model systems have provided promising targets in designing genetic and pharmacologic strategies for systemic or adjuvant nonsurgical treatment. Here we will review the current literature and provide insights to future possibilities and limitations of therapeutic applications.",
keywords = "Apert syndrome, Craniosynostosis, Fibroblast growth factor receptor, Inhibitor, Mutation, Surgery, Treatment",
author = "Heather Melville and Yingli Wang and Taub, {Peter J.} and Jabs, {Ethylin Wang}",
year = "2010",
month = "12",
doi = "10.1002/ajmg.a.33703",
language = "English (US)",
volume = "152 A",
pages = "3007--3015",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Genetic basis of potential therapeutic strategies for craniosynostosis

AU - Melville, Heather

AU - Wang, Yingli

AU - Taub, Peter J.

AU - Jabs, Ethylin Wang

PY - 2010/12

Y1 - 2010/12

N2 - Craniosynostosis, the premature fusion of one or more cranial sutures, is a common malformation of the skull that can result in facial deformity and increased intracranial pressure. Syndromic craniosynostosis is present in -15% of craniosynostosis patients and often is clinically diagnosed by neurocranial phenotype as well as various other skeletal abnormalities. The most common genetic mutations identified in syndromic craniosynostosis involve the fibroblast growth factor receptor (FGFR) family with other mutations occurring in genes for transcription factors TWIST, MSX2, and GLI3, and other proteins EFNB1, RAB23, RECQL4, and POR, presumed to be involved either upstream or downstream of the FGFR signaling pathway. Both syndromic and nonsyndromic craniosynostosis patients require early diagnosis and intervention. The premature suture fusion can impose pressure on the growing brain and cause continued abnormal postnatal craniofacial development. Currently, treatment options for craniosynostosis are almost exclusively surgical. Serious complications can occur in infants requiring either open or endoscopic repair and therefore the development of nonsurgical techniques is highly desirable although arguably difficult to design and implement. Genetic studies of aberrant signaling caused by mutations underlying craniosynostosis in in vitro calvarial culture and in vivo animal model systems have provided promising targets in designing genetic and pharmacologic strategies for systemic or adjuvant nonsurgical treatment. Here we will review the current literature and provide insights to future possibilities and limitations of therapeutic applications.

AB - Craniosynostosis, the premature fusion of one or more cranial sutures, is a common malformation of the skull that can result in facial deformity and increased intracranial pressure. Syndromic craniosynostosis is present in -15% of craniosynostosis patients and often is clinically diagnosed by neurocranial phenotype as well as various other skeletal abnormalities. The most common genetic mutations identified in syndromic craniosynostosis involve the fibroblast growth factor receptor (FGFR) family with other mutations occurring in genes for transcription factors TWIST, MSX2, and GLI3, and other proteins EFNB1, RAB23, RECQL4, and POR, presumed to be involved either upstream or downstream of the FGFR signaling pathway. Both syndromic and nonsyndromic craniosynostosis patients require early diagnosis and intervention. The premature suture fusion can impose pressure on the growing brain and cause continued abnormal postnatal craniofacial development. Currently, treatment options for craniosynostosis are almost exclusively surgical. Serious complications can occur in infants requiring either open or endoscopic repair and therefore the development of nonsurgical techniques is highly desirable although arguably difficult to design and implement. Genetic studies of aberrant signaling caused by mutations underlying craniosynostosis in in vitro calvarial culture and in vivo animal model systems have provided promising targets in designing genetic and pharmacologic strategies for systemic or adjuvant nonsurgical treatment. Here we will review the current literature and provide insights to future possibilities and limitations of therapeutic applications.

KW - Apert syndrome

KW - Craniosynostosis

KW - Fibroblast growth factor receptor

KW - Inhibitor

KW - Mutation

KW - Surgery

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=78649677069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649677069&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.33703

DO - 10.1002/ajmg.a.33703

M3 - Article

C2 - 21082653

AN - SCOPUS:78649677069

VL - 152 A

SP - 3007

EP - 3015

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

IS - 12

ER -